2.A Protocol of Korean JOint RegistrY for ALZheimer’s Treatment and Diagnostics (JOY-ALZ)
Geon Ha KIM ; Jung-Min PYUN ; Danbee KANG ; Sung Hoon KANG ; Seong-Ho KOH ; Jae Seung KIM ; So Young MOON ; Won-Jin MOON ; Young Ho PARK ; YongSoo SHIM ; Dong Won YANG ; Young Chul YOUN ; Young Hee JUNG ; Hanna CHO ; Hojin CHOI ; Jae-Sung LIM ; Kee Hyung PARK ; Seong Hye CHOI
Dementia and Neurocognitive Disorders 2026;25(1):25-41
Background:
and Purpose: To assess the long-term effectiveness, safety, and economic viability of recently approved Alzheimer’s disease (AD) therapies, as well as to evaluate the real-world application of novel diagnostics among AD patients with diverse comorbidities, comprehensive real-world data (RWD) analysis is essential. The Korean JOint RegistrY for ALZheimer’s Treatment and Diagnostics (JOY-ALZ) endeavors to create a registry of RWD derived from clinical practice on new diagnostic methods and therapeutic agents for AD introduced in Korea since 2021.
Methods:
Participants must fulfill all the following: 1) be at least 19 years old; 2) be actively receiving, scheduled to initiate, or undergoing evaluation for any AD disease-modifying treatment; 3) have completed amyloid positron emission tomography or cerebrospinal fluid AD immunoassay (a positive result is not essential for participation); 4) have a clinical classification of cognitively unimpaired, mild cognitive impairment, or probable AD dementia. Data generated during routine care is segmented into a minimum dataset, extended dataset, and research-only dataset requiring extra consent. Assessments encompass clinical, cognitive, functional, neurobehavioral, neuroimaging, and biomarker evaluations, in addition to systematic monitoring of new AD treatments and their safety.Data are collected and monitored at baseline, at semiannual intervals during the initial 2 years, and then annually up to 2034. To date, 46 medical centers will participate in JOY-ALZ.
Conclusions
JOY-ALZ is expected to promote understanding of the long-term clinical outcomes, safety, and cost-effectiveness of recently introduced diagnostics and treatments for AD, thereby supporting the progress of precision medicine in AD care and diagnosis.
4.Correcting unfolded helix in a 22-year-old male patient: a case report
Archives of Aesthetic Plastic Surgery 2025;31(1):17-20
An unfolded helix is an auricular deformity that has garnered relatively little research focus. This study introduces a surgical technique designed to correct flat helix deformities. A 22-year-old male with bilateral unfolded helixes and prominent ears underwent this procedure under local anesthesia. The surgery employed a posterior auricular approach, with incisions extending from the upper pole of the ear to the concha. Along the helical rim, four radiating incisions were made, followed by oblique cuts in the cartilage and the creation of triangular flaps through advancement. The free edges of the cartilage were then overlapped and sutured together. Post-surgery, the patient experienced a successful recovery, evidenced by the curling of the helix and the absence of complications. This surgical technique is not only effective for correcting unfolded helixes but can also be efficiently performed under local anesthesia.
5.Correcting unfolded helix in a 22-year-old male patient: a case report
Archives of Aesthetic Plastic Surgery 2025;31(1):17-20
An unfolded helix is an auricular deformity that has garnered relatively little research focus. This study introduces a surgical technique designed to correct flat helix deformities. A 22-year-old male with bilateral unfolded helixes and prominent ears underwent this procedure under local anesthesia. The surgery employed a posterior auricular approach, with incisions extending from the upper pole of the ear to the concha. Along the helical rim, four radiating incisions were made, followed by oblique cuts in the cartilage and the creation of triangular flaps through advancement. The free edges of the cartilage were then overlapped and sutured together. Post-surgery, the patient experienced a successful recovery, evidenced by the curling of the helix and the absence of complications. This surgical technique is not only effective for correcting unfolded helixes but can also be efficiently performed under local anesthesia.
6.Correcting unfolded helix in a 22-year-old male patient: a case report
Archives of Aesthetic Plastic Surgery 2025;31(1):17-20
An unfolded helix is an auricular deformity that has garnered relatively little research focus. This study introduces a surgical technique designed to correct flat helix deformities. A 22-year-old male with bilateral unfolded helixes and prominent ears underwent this procedure under local anesthesia. The surgery employed a posterior auricular approach, with incisions extending from the upper pole of the ear to the concha. Along the helical rim, four radiating incisions were made, followed by oblique cuts in the cartilage and the creation of triangular flaps through advancement. The free edges of the cartilage were then overlapped and sutured together. Post-surgery, the patient experienced a successful recovery, evidenced by the curling of the helix and the absence of complications. This surgical technique is not only effective for correcting unfolded helixes but can also be efficiently performed under local anesthesia.
7.Vertebral Artery Dissection with Acute Ischemic Stroke after COVID-19 Vaccination: Three Case Reports
Hong Keun YOO ; Ji Hyun KIM ; Young Joo LEE ; Kyu Yong LEE ; Seong Ho KOH ; Seong Ho PARK ; Hojin CHOI ; Hyuk Sung KWON
Journal of Neurosonology and Neuroimaging 2025;17(2):37-39
SARS-CoV-2 is a global pandemic with high mortality and prevalence. Although the disease severity has weakened, it remains a significant global health burden as an endemic disease. Several reports have explored the relationship between intracranial artery dissection and SARS-CoV-2 infection; however, an association with SARS-CoV-2 vaccination has not been established. Here, we describe three cases of vertebral arterial dissection with acute ischemic stroke after SARS-CoV-2 vaccination. This report aimed to raise the clinical awareness of this potential adverse effect, which may facilitate earlier diagnosis and intervention.
8.Clinical consequence of hypophosphatemia during antiviral therapy for chronic hepatitis B
Mee Yeon PARK ; Hojin JEON ; Kyungho PARK ; Junseok JEON ; Minsu PARK ; Sang Ah CHI ; Kyunga KIM ; Dong Hyun SINN ; Jung Eun LEE ; Geum-Youn GWAK ; Wooseong HUH ; Yoon-Goo KIM ; Hye Ryoun JANG
Kidney Research and Clinical Practice 2025;44(1):123-131
Antiviral therapy is an essential treatment for chronic hepatitis B (CHB) infection. Although hypophosphatemia is an important adverse effect of antiviral agents, its clinical significance remains unclear. We investigated the incidence and clinical consequences of hypophosphatemia in a large cohort of CHB patients. Methods: This retrospective cohort study included CHB patients who started antiviral therapy between 2005 and 2015 and continued it for at least 1 year. Patients with decompensated liver cirrhosis, diabetes mellitus, hypertension, concomitant diuretic administration, and end-stage renal disease were excluded. The primary outcome was a change in renal function. Secondary outcomes included the incidence of infection and changes in serum potassium, uric acid, and total carbon dioxide (tCO2). Results: Among the 4,335 patients, hypophosphatemia developed in 75 (1.7%). During the median 2-year follow-up period, patients with hypophosphatemia showed a lower estimated glomerular filtration rate than those in the control group. The incidence of infection and changes in serum potassium, uric acid, and tCO2 were similar between groups. Conclusion: Hypophosphatemia was associated with a renal function decline in patients with CHB receiving antiviral therapy.
9.Lecanemab: Appropriate Use Recommendations by Korean Dementia Association
Kee Hyung PARK ; Geon Ha KIM ; Chi-Hun KIM ; Seong-Ho KOH ; So Young MOON ; Young Ho PARK ; Sang Won SEO ; Bora YOON ; Jae-Sung LIM ; Byeong C. KIM ; Hee-Jin KIM ; Hae Ri NA ; YongSoo SHIM ; YoungSoon YANG ; Chan-Nyoung LEE ; Hak Young RHEE ; San JUNG ; Jee Hyang JEONG ; Hojin CHOI ; Dong Won YANG ; Seong Hye CHOI
Dementia and Neurocognitive Disorders 2024;23(4):165-187
Lecanemab (product name Leqembi ® ) is an anti-amyloid monoclonal antibody treatment approved for use in Korea for patients with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease. The Korean Dementia Association has created recommendations for the appropriate use of lecanemab to assist clinicians. These recommendations include selecting patients for administration, necessary pre-administration tests and preparations,administration methods, monitoring for amyloid related imaging abnormalities (ARIA), and communication with patients and caregivers. Lecanemab is recommended for patients with MCI or mild dementia who confirmed positive amyloid biomarkers, and should not be administered to patients with severe hypersensitivity to lecanemab or those unable to undergo magnetic resonance imaging (MRI) evaluation. To predict the risk of ARIA before administration, apolipoprotein E genotyping is conducted, and regular brain MRI evaluations are recommended to monitor for ARIA during treatment. The most common adverse reactions are infusion-related reactions, which require appropriate management upon occurrence. Additional caution is needed when co-administering with anticoagulants or tissue plasminogen activator due to the risk of macrohemorrhage. Clinicians should consider the efficacy and necessary conditions for administration, as well as the safety of lecanemab, to make a comprehensive decision regarding its use.
10.Lecanemab: Appropriate Use Recommendations by Korean Dementia Association
Kee Hyung PARK ; Geon Ha KIM ; Chi-Hun KIM ; Seong-Ho KOH ; So Young MOON ; Young Ho PARK ; Sang Won SEO ; Bora YOON ; Jae-Sung LIM ; Byeong C. KIM ; Hee-Jin KIM ; Hae Ri NA ; YongSoo SHIM ; YoungSoon YANG ; Chan-Nyoung LEE ; Hak Young RHEE ; San JUNG ; Jee Hyang JEONG ; Hojin CHOI ; Dong Won YANG ; Seong Hye CHOI
Dementia and Neurocognitive Disorders 2024;23(4):165-187
Lecanemab (product name Leqembi ® ) is an anti-amyloid monoclonal antibody treatment approved for use in Korea for patients with mild cognitive impairment (MCI) or mild dementia due to Alzheimer's disease. The Korean Dementia Association has created recommendations for the appropriate use of lecanemab to assist clinicians. These recommendations include selecting patients for administration, necessary pre-administration tests and preparations,administration methods, monitoring for amyloid related imaging abnormalities (ARIA), and communication with patients and caregivers. Lecanemab is recommended for patients with MCI or mild dementia who confirmed positive amyloid biomarkers, and should not be administered to patients with severe hypersensitivity to lecanemab or those unable to undergo magnetic resonance imaging (MRI) evaluation. To predict the risk of ARIA before administration, apolipoprotein E genotyping is conducted, and regular brain MRI evaluations are recommended to monitor for ARIA during treatment. The most common adverse reactions are infusion-related reactions, which require appropriate management upon occurrence. Additional caution is needed when co-administering with anticoagulants or tissue plasminogen activator due to the risk of macrohemorrhage. Clinicians should consider the efficacy and necessary conditions for administration, as well as the safety of lecanemab, to make a comprehensive decision regarding its use.

Result Analysis
Print
Save
E-mail